← Leaderboards
Scott J Antonia
Duke University
$4,663,305
Attributed
$8,956,858
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $877.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,956,858 · 9
By mechanism
R01$3,676,800 · 3
U01$3,290,785 · 1
K24$945,552 · 1
R21$570,260 · 1
P30$328,461 · 2
R03$145,000 · 1
Top collaborators
- Alexander Robertson Allan Anderson5 shared
- Robert A Gatenby5 shared
- Amer Aziz Beg4 shared
- Dmitry Isaac Gabrilovich3 shared
- Fang Li3 shared
- Yunyan Jennifer Jennifer Zhang3 shared
Most similar at Duke University
Same institution · by research overlap
- Michael Barry Kastan$65,974,699
- Darell D Bigner$25,397,506
- Jiaoti Huang$7,876,254
- Tim Clay$4,101,259
- Chuan-Yuan Li$14,248,346
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyClinical TrialsMalignant NeoplasmsTumorResponseImmune ResponseBaseMalignant Neoplasm Of LungCancer PatientNeoplastic CellT-LymphocytePre-ClinicalImmuneImmunotherapeutic AgentSignal TransductionTumor MicroenvironmentClinical ResearchAntigensSiteCellsNon-Small-Cell Lung CarcinomaResistanceOncologyPathway Interactions
Grant awards (30)
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy$535,077
R01 · FY2025 · CA
Immuno/Oncology (IO)$70,009
P30 · FY2025 · CA · contact PI
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy$508,324
R01 · FY2024 · CA
Precision Cancer Medicine and Investigational Therapeutics$59,438
P30 · FY2024 · CA · contact PI
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy$524,375
R01 · FY2023 · CA
Precision Cancer Medicine and Investigational Therapeutics$67,578
P30 · FY2023 · CA · contact PI
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance$591,459
U01 · FY2022 · CA
Precision Cancer Medicine and Investigational Therapeutics$67,206
P30 · FY2022 · CA · contact PI
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance$756,968
U01 · FY2021 · CA
Precision Cancer Medicine and Investigational Therapeutics$64,230
P30 · FY2021 · CA · contact PI
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance$603,529
U01 · FY2020 · CA
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance$650,786
U01 · FY2019 · CA
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance$688,043
U01 · FY2018 · CA
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$189,200
R01 · FY2018 · CA · contact PI
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$259,646
R01 · FY2017 · CA · contact PI
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$189,200
R01 · FY2017 · CA · contact PI
Regulation of Tumor Microenvironment in Cancer$380,866
R01 · FY2016 · CA
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$321,654
R01 · FY2016 · CA · contact PI
Regulation of Tumor Microenvironment in Cancer$373,604
R01 · FY2015 · CA
Regulation of Tumor Microenvironment in Cancer$394,854
R01 · FY2014 · CA
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer$171,205
K24 · FY2012 · CA · contact PI
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer$171,205
K24 · FY2011 · CA · contact PI
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer$167,791
K24 · FY2010 · CA · contact PI
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer$164,476
K24 · FY2009 · CA · contact PI
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer$109,616
K24 · FY2009 · CA · contact PI
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer$161,259
K24 · FY2008 · CA · contact PI
Combination Immunotherapy for Lung Cancer$280,935
R21 · FY2007 · CA · contact PI
Combination Immunotherapy for Lung Cancer$289,325
R21 · FY2006 · CA · contact PI
B7 1 GENE MODIFIED TUMOR CELL VACCINE FOR RENAL CELL CA$72,500
R03 · FY2002 · CA
B7 1 GENE MODIFIED TUMOR CELL VACCINE FOR RENAL CELL CA$72,500
R03 · FY2000 · CA